Last updated on November 2018

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy


Brief description of study

The objective of this study is to assess the reduction in insulin dose from baseline at Week 24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when ipragliflozin is administered once daily for 24 weeks in patients with type 2 diabetes mellitus receiving insulin therapy.

Clinical Study Identifier: NCT02847091

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Inc.

Site JP00002
Tochigi, Japan

Astellas Pharma Inc.

Site JP00005
Tochigi, Japan

Astellas Pharma Inc.

Site JP00013
Tochigi, Japan